Immix Biopharma Inc (IMMX) - Total Assets
Based on the latest financial reports, Immix Biopharma Inc (IMMX) holds total assets worth $239.11 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Immix Biopharma Inc - Total Assets Trend (2019–2025)
This chart illustrates how Immix Biopharma Inc's total assets have evolved over time, based on quarterly financial data. Also see IMMX company net worth for the company's overall valuation and market capitalisation.
Immix Biopharma Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Immix Biopharma Inc's total assets of $239.11 Million consist of 96.6% current assets and 3.4% non-current assets. Review IMMX total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 89.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Immix Biopharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Immix Biopharma Inc stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Immix Biopharma Inc's current assets represent 96.6% of total assets in 2025, a decrease from 99.0% in 2019.
- Cash Position: Cash and equivalents constituted 89.6% of total assets in 2025, up from 77.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Immix Biopharma Inc Competitors by Total Assets
Key competitors of Immix Biopharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Immix Biopharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 25.13 | 1.23 | 0.04 |
| Quick Ratio | 25.13 | 1.23 | 0.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $224.49 Million | $2.32 Million | $-6.22 Million |
Immix Biopharma Inc - Advanced Valuation Insights
This section examines the relationship between Immix Biopharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.13 |
| Latest Market Cap to Assets Ratio | 8.40 |
| Asset Growth Rate (YoY) | 356.9% |
| Total Assets | $104.84 Million |
| Market Capitalization | $880.65 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Immix Biopharma Inc's assets at a significant premium (8.40x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Immix Biopharma Inc's assets grew by 356.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Immix Biopharma Inc (2019–2025)
The table below shows the annual total assets of Immix Biopharma Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $104.84 Million | +356.86% |
| 2024-12-31 | $22.95 Million | +15.17% |
| 2023-12-31 | $19.93 Million | +33.65% |
| 2022-12-31 | $14.91 Million | -18.05% |
| 2021-12-31 | $18.19 Million | +3271.42% |
| 2020-12-31 | $539.60K | -42.78% |
| 2019-12-31 | $942.94K | -- |
About Immix Biopharma Inc
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.